A randomised phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in-situ (DCIS) of the breast

DCIS is the name for a condition in which abnormal cells are contained within the milk ducts of the breast. DCIS is not an invasive breast cancer however, if left untreated, DCIS has the potential to turn into an invasive breast cancer. This is why we treat DCIS to reduce the risk of developing invasive cancer. Radiation treatment after surgery for DCIS improves the chances of not developing further cancer in that breast. However, this treatment does not completely cure everyone who has it. In some people DCIS comes back, despite having this treatment. Doctors are looking for better ways to treat people with DCIS. In this research project, the researchers will test whether an additional dose of radiation called a boost given to the part of the breast that had DCIS within it improves the chances of not having the cancer come back in the breast.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Breast International Group (BIG 3-07); Canadian Cancer Trials Group (CCTG MA33); European Organisation for Research and Treatment of Cancer (EORTC Trial 22085-10083); Scottish Cancer Trials Breast Group (SCTBG); All-Ireland Cooperative Oncology Research Group (ICORG); and the International Breast Cancer Study Group (IBCSG38)

Participating Centres

Final Accrual

1608

Current Accrual

Closing Date of Accrual

June 2014

Trial Chairperson

Prof Boon Chua, Director of Cancer and Haematology Services at UNSW and Prince of Wales Hospital, Sydney

Trial Contact

DCIS@trog.com.au

Clinical Trial Registration

Related Post

August 2, 2022

Celebrating and bringing radiation medicine research to the forefront at our 2022 ASM

After a hiatus from in-person events due to COVID-19

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a